165 related articles for article (PubMed ID: 8625219)
1. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
Yonemura Y; Nojima N; Kaji M; Fujimura T; Itoh H; Ninomiya I; Miyazaki I; Endo Y; Sasaki T
Cancer; 1995 Sep; 76(6):941-53. PubMed ID: 8625219
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer].
Itoh H; Yonemura Y; Tsuchihara K; Kawamura T; Nojima N; Kaji M; Fushida S; Nishimura G; Fujimura T; Miwa K
Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():124-9. PubMed ID: 7611774
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T
Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Nozaki S; Endo Y; Kawashiri S; Nakagawa K; Yamamoto E; Yonemura Y; Sasaki T
Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
7. Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer.
Shin SJ; Kim KO; Kim MK; Lee KH; Hyun MS; Kim KJ; Choi JH; Song HS
Jpn J Clin Oncol; 2005 Jun; 35(6):342-8. PubMed ID: 15937032
[TBL] [Abstract][Full Text] [Related]
8. [Expression of E-cadherin and uPA and their prognostic value in carcinoma of human larynx.].
Wu HY; Shen XH; Ni RS; Qian XY; Gao X
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Dec; 44(12):1024-8. PubMed ID: 20193619
[TBL] [Abstract][Full Text] [Related]
9. [Expression of cyclooxygenase-2 and urokinase plasminogen activator in gastric carcinoma and the clinical significance thereof].
Zhang FH; Zhou YN; Li GZ; Li Q; Lu B; Zhang ZY; Wu ZQ; Fan P; Hao TJ
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(46):3279-82. PubMed ID: 19159555
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Okusa Y; Ichikura T; Mochizuki H
Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785
[TBL] [Abstract][Full Text] [Related]
12. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
13. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao E; Han D; Yu Z; Fan E; Li Y; Zhou Z
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Nov; 16(11):599-602. PubMed ID: 15515548
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Horch HH
Mund Kiefer Gesichtschir; 2004 May; 8(3):180-90. PubMed ID: 15138856
[TBL] [Abstract][Full Text] [Related]
16. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.
Zhang L; Zhao ZS; Ru GQ; Ma J
World J Gastroenterol; 2006 Jul; 12(25):3970-6. PubMed ID: 16810742
[TBL] [Abstract][Full Text] [Related]
17. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
18. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
19. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Look MP; van Putten WL; Duffy MJ; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder ME; Manders P; Fiets WE; Blankenstein MA; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex LV; Klijn JG; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens JA
J Natl Cancer Inst; 2002 Jan; 94(2):116-28. PubMed ID: 11792750
[TBL] [Abstract][Full Text] [Related]
20. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
